Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Incidence of Hypertension and Proteinuria in Bevacizumab- and Bevacizumab Biosimilar-Treated Cohorts

2021 Year in Review - Biosimilars - Biosimilars

Preliminary findings of this retrospective study indicate that treatment with bevacizumab reference product may be associated with a higher risk for hypertension and proteinuria, whereas treatment with bevacizumab biosimilars correlated with shorter onset of these adverse events.

Comparative safety analysis of the bevacizumab biosimilars and the reference product is limited. Therefore, a retrospective study sought to evaluate the incidence of hypertension and proteinuria and their associated risk factors in patients treated with reference versus biosimilar bevacizumab.

This retrospective study identified patients with gastrointestinal cancer who were treated with either reference bevacizumab or biosimilar bevacizumab between January 2019 and July 2020 at Roswell Park Comprehensive Cancer Center. In the analysis, electronic health records were searched for the presence or absence of hypertension and proteinuria and time to event. To assess the risk association with hypertension and proteinuria, information including demographics, hypertension- and proteinuria-related risk factors, bevacizumab-containing chemotherapy regimen, and bevacizumab dosing were identified.

A total of 75 patients were included in the analysis; of these, 42 patients received bevacizumab and 33 patients received bevacizumab biosimilars. Hypertension occurred more frequently in the bevacizumab reference group versus the biosimilar group (52.4% vs 36.4%; P = .242); however, the difference was not statistically significant. After treatment initiation, the median time to hypertension was significantly longer in the bevacizumab reference group versus the biosimilar group (84 days vs 24.5 days; P = .0064). A slightly higher proportion of patients in the bevacizumab reference group developed proteinuria (35.7% vs 30%; P = .7193). The median onset of proteinuria was significantly longer in the bevacizumab reference group than in the biosimilar group (213 days vs 53.5 days; P = .0022). Risk assessments showed that a history of hypertension was associated with increased risk for further hypertension, whereas underlying renal dysfunction increased the risk for proteinuria.

These results suggest a higher risk for hypertension and proteinuria with the bevacizumab reference product, although the differences did not reach statistical significance and indicate a shorter onset of these adverse events with the bevacizumab biosimilars. Further studies in larger cohorts are warranted to confirm these results.

Source: Man Y, Han Y, Mukherjee S, et al. Incidence of hypertension and proteinuria in patients treated with bevacizumab versus bevacizumab biosimilar. J Clin Oncol. 2021;39(suppl_3):83.

Related Items
Adoption of Biosimilars—Why the Delay?
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Editorial, Biosimilars
Comparing Single-Center Outcomes Between Reference and Biosimilar Granulocyte Colony-Stimulating Factor Drugs Used for Autologous Stem-Cell Mobilization
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Original Article, Biosimilars, Transplant
Pharmacist-Driven Intervention Significantly Increases Biosimilar Adoption in Clinical Practice
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Biosimilars, Oncology Pharmacy Programs, ASCO Highlights
Oncologists’ Common Misconceptions About Biosimilars Revealed in a Recent Survey
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Biosimilars, ASCO Highlights
2021 in Review
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Real-World Data Showed Comparable pCR Rates with Neoadjuvant Chemotherapy plus Trastuzumab-dkst versus Trastuzumab
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Cost-Efficiency Analysis of Switching from Reference Pegfilgrastim to Pegfilgrastim-jmdb
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Real-World Evidence of Cardiac Safety of Trastuzumab Biosimilar Trastuzumab-anns in Breast Cancer
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Same-Day Pegfilgrastim-cbqv Administration Is Feasible in Patients with Breast Cancer Receiving Myelosuppressive Chemotherapy Regimens
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Real-World Evidence of Bevacizumab-awwb Use in a Population of Patients with Cancer
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.